Identifying the toxicity profile of a compound is a necessity across industries and the various stages of drug development. Early stage mechanism-based in vitro assays can not only speed up the compound development pipeline, but also can reduce animal testing requirements. Information about the mode-of-action of genotoxic compounds can be vital for both screening and regulatory applications.
In this webinar, Miltenyi Biotec and Toxys will highlight the potential of using flow cytometry for high content toxicity analysis. We will introduce the ToxTracker® assay and you will learn about the opportunities, advantages and challenges faced when using this assay for mechanistic toxicity testing.
Before joining Miltenyi Biotec as a Global Product Manager for Flow Cytometry Reagents in 2018, Dr. Urmi Roy worked as a Post Doc at the Helmholtz Centre Braunschweig, Germany, where she specialized in mucosal immunology/gut microbiota. She received her Ph.D. in Immunology at the TU Braunschweig in 2017.
Dr. Giel Hendriks is the founder and CEO of Toxys, a Dutch biotech company that develops and offers innovative in vitro assays for toxicological research. He completed his Ph.D in molecular cell biology at Utrecht University and worked as senior scientist in genetic toxicology at the Leiden University Medical Center.